RDY:NYE-Dr. Reddy’s Laboratories Ltd ADR (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 15.67

Change

+0.18 (+1.16)%

Market Cap

USD 13.11B

Volume

1.33M

Analyst Target

USD 47.58
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.42 (+0.26%)

USD 74.37B
HLN Haleon plc

+0.02 (+0.21%)

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.24B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

+0.02 (+0.17%)

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.06 (+0.77%)

USD 3.59B
BHC Bausch Health Companies Inc

+0.05 (+0.67%)

USD 2.75B
CPHI China Pharma Holdings Inc

+0.01 (+5.00%)

USD 3.69M
YCBD cbdMD Inc

+0.01 (+2.28%)

USD 1.96M
PBH Prestige Brand Holdings Inc

+0.19 (+0.24%)

N/A

ETFs Containing RDY

EMSD 0.03 % 0.00 %

N/A

N/A
BICK 0.00 % 0.64 %

N/A

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
PPEM PortfolioPlus Emerging Ma.. 0.00 % 0.00 %

+0.05 (+0%)

USD 1.04M
ZID:CA BMO MSCI India ESG Leader.. 0.00 % 0.69 %

N/A

CAD 0.38B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.60% 60% D- 66% D+
Dividend Return 4.13% 67% D+ 59% D-
Total Return 16.74% 53% F 68% D+
Trailing 12 Months  
Capital Gain 16.45% 60% D- 73% C
Dividend Return 4.27% 67% D+ 59% D-
Total Return 20.73% 67% D+ 75% C
Trailing 5 Years  
Capital Gain 93.41% 86% B+ 86% B+
Dividend Return 21.60% 80% B- 68% D+
Total Return 115.01% 93% A 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 9.26% 67% D+ 63% D
Dividend Return 10.56% 67% D+ 61% D-
Total Return 1.30% 67% D+ 32% F
Risk Return Profile  
Volatility (Standard Deviation) 25.37% 67% D+ 43% F
Risk Adjusted Return 41.62% 67% D+ 56% F
Market Capitalization 13.11B 70% C- 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.